Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:51:08 EDT Sun 24 Jun 2018
Enter Symbol
or Name
USA
CA



Q:GILD - Gilead Sciences, Inc. - http://www.gilead.com04:51:08 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.370.81 · 71.300.271.07-0.45-0.66,118.9435,80540,55171.69  71.76  70.8389.54  64.2719:37:28Jun 1415 min RT 2¢

Recent Trades - Last 10 of 40551
Time ETExPriceChangeVolume
19:37:28Q71.30-0.2220
19:15:44Q70.81-0.71300
19:13:35Q70.81-0.7115
19:13:35Q70.81-0.71285
17:56:24Q71.34-0.183
16:50:08Q70.8001-0.7199100
16:43:46Q71.07-0.454,285
16:41:35Q71.07-0.451
16:41:35Q71.07-0.451
16:34:55Q71.07-0.45210

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-06-14 08:30U:GILDNews ReleaseConsolidated Research: 2018 Summary Expectations for Encana, Netflix, Veon, The Walt Disney, Gilead Sciences, and Cloudera — Fundamental Analysis, Key Performance Indications
2018-06-11 08:30U:GILDNews ReleaseGilead Sciences ’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
2018-06-04 17:00U:GILDNews ReleaseGilead Sciences Announces Leadership Changes in Corporate Development and Strategy
2018-06-04 09:00U:GILDNews ReleaseKite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
2018-06-04 09:00U:GILDNews ReleaseKite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
2018-05-30 16:01U:GILDNews ReleaseGilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13
2018-05-30 16:01U:GILDNews ReleaseGilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis
2018-05-30 01:00U:GILDNews ReleaseChina Drug Administration Approves Epclusa ® (Sofosbuvir/Velpatasvir), Gilead ’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection